Additionally, in the alliance, Pfizer will apply VirtualScopics’ technology to ongoing clinical research in an effort to identify and validate image-based biomarkers correlating to clinical outcomes. The biomarkers may then be used to assess the efficacy of new pharmaceutical compounds in the clinical trial process while reducing drug development costs and the time to market.
This strategic relationship expands ongoing collaborative efforts between Pfizer and VirtualScopics to correlate image-based biomarkers to disease progression in several therapeutic areas. With novel approaches for semi-automated approaches for clinical image analysis, a significant impact in quality and execution of imaging trials has been demonstrated.
Robert Klimasewski, president and CEO of VirtualScopics, stated, “We are delighted that we will continue our strategic alliance with Pfizer. Over the past three years, the relationship has proven to be a significant benefit to both parties and to the medical industry at large through improved drug development.”